Natural Killer/Natural Killer-Like T-Cell Lymphoma, CD56+, Presenting in the Skin: An Increasingly Recognized Entity With an Aggressive Course
- 15 April 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (8) , 2179-2188
- https://doi.org/10.1200/jco.2001.19.8.2179
Abstract
PURPOSE: To describe and identify the clinical and pathologic features of prognostic significance for natural killer (NK) and NK-like T-cell (NK/T-cell) lymphoma presenting in the skin.PATIENTS AND METHODS: This study was a retrospective review of 30 patients with CD56+ lymphomas initially presenting with cutaneous lesions, with analysis of clinical and histopathologic parameters.RESULTS: The median survival for all patients was 15 months. Those with extracutaneous manifestations at presentation (11 patients) had a shorter median survival of 7.6 months as compared with those without extracutaneous involvement (17 patients), who had a more favorable median survival of 44.9 months (P = .0001). Age, gender, extent of cutaneous involvement, and initial response to therapy had no statistically significant effect on survival. Seven patients (24%) had detectable Epstein-Barr virus (EBV) within neoplastic cells. The patients with tumor cells that coexpress CD30 (seven patients) have not yet reached a median survival after 35 months of follow-up as compared with those with CD30− tumor cells (20 patients), who had a median survival of 9.6 months (P < .02). Routine histopathologic characteristics had no prognostic significance nor did the presence of CD3ε, EBV, or multidrug resistance.CONCLUSION: NK/T-cell lymphoma is an aggressive neoplasm; however, a subset with a more favorable outcome is identified in this study. The presence of extracutaneous disease at presentation is the most important clinical variable and portends a poor prognosis. The extent of initial skin involvement does not reliably predict outcome. Patients from the United States with NK/T-cell lymphoma presenting in the skin have a low incidence of demonstrable EBV in their tumor cells. Patients with coexpression of CD30 in CD56 lymphomas tend to have a more favorable outcome.Keywords
This publication has 32 references indexed in Scilit:
- Co‐expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven casesJournal of Cutaneous Pathology, 2000
- CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous diseaseBritish Journal of Dermatology, 1997
- Lymphomatoid Papulosis and Cutaneous CD30+ LymphomaThe American Journal of Dermatopathology, 1996
- Epstein‐Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritisArthritis & Rheumatism, 1996
- Inconsistent association of Epstein‐Barr virus with CD56 (NCAM)‐positive angiocentric lymphoma occuring in sites other than the upper and lower respiratory tractHistopathology, 1996
- Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell LymphomasThe American Journal of Surgical Pathology, 1996
- NK1.1+ T cell receptor-alpha/beta+ cells: new clues to their origin, specificity, and function.The Journal of Experimental Medicine, 1995
- Clinicopathologic Study of CD56 (NCAM)-Positive Angiocentric Lymphoma Occurring in Sites Other than the Upper and Lower Respiratory TractThe American Journal of Surgical Pathology, 1995
- T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus InfectionsNew England Journal of Medicine, 1988
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965